10 registrations that name ashwagandha as a study arm and are recruiting or about to, as ClinicalTrials.gov listed them on Oct 20, 2026. Read each listing for its full criteria and current status.
Kymata never assesses eligibility. Each listing names its own criteria; only its study team can say whether someone can join. Trial doses are given under the trial's monitoring and are not a schedule for anyone outside it.
Filter 10 registrations
Status
Phase
7US sites across 3 states
1
2 to 4
5 to 19
20 or more
All 10 registrations
RecruitingNCT07441070
Effect of Ashwagandha Root Extract on Stress, Anxiety, and Sleep Quality in Adults Experiencing Minority Stress
No phase
SF Research Institute, Inc.
About 80 people
Starts Apr 29, 2026 (estimated)
In plain words A study of ashwagandha in people 18 to 45, run by SF Research Institute, Inc.. It plans to enroll about 80 people at 1 US site.
Who it lists and where
Who the trial lists, as registered
Lists people 18 to 45; healthy volunteers accepted. Conditions: Minority Stress; Psychological Stress; Anxiety.
Self-identified as a sexual or gender minority (e.g., lesbian, gay, bisexual, transgender, queer, non-binary).
Aged 18-45 years.
Moderate to high perceived stress levels (PSS-10 total score >14).
Willing to provide written informed consent.
The exclusion criteria are on the listing.
What it tests, as registered
Ashwagandha Root Extract; Placebo Capsule
Registered summary
Sexual and gender minority adults often experience elevated levels of chronic stress due to stigma, discrimination, and social adversity, commonly referred to as minority stress. This persistent stress is associated with increased anxiety, mood disturbances, impaired sleep quality, and reduced quality of life. There is a need for safe, non-pharmacological interventions that can support mental well-being in this population. The full summary is on the listing.
Where, as registered
1 US site in 1 state.
RecruitingNCT05610735
Combination Therapy for Recurrent Ovarian Cancer
Phase 1 and 2
Sham Sunder Kakar
About 72 people
Started Sep 25, 2024
In plain words A Phase 1 and 2 study of ashwagandha in female participants 18 and older, run by Sham Sunder Kakar. It plans to enroll about 72 people at 1 US site.
Who it lists and where
Who the trial lists, as registered
Lists female participants 18 and older. Conditions: Recurrent Ovarian Cancer.
Signed approved informed consent document stating that they understand the investigational nature of the treatment program before entering study
Female patients, age ≥ 18 years
Pathological confirmed ovarian, fallopian tube, or primary peritoneal carcinoma with the one of the following histologic types: high grade papillary serous carcinoma, low grade papillary serous carcinoma, high grade mucinous carcinoma, low…
Received at least one line chemotherapy, which must be a platinum containing regimen and develop platinum resistance.
15 more inclusion criteria and the exclusion criteria are on the listing.
What it tests, as registered
DOXIL; Withaferin A; Ashwagandha; Combination of ASWD and DOXIL
Registered summary
The proposed study "combination therapy with liposomal doxorubicin and withaferin A (Ashwagandha, ASWD) in recurrent ovarian cancer" is focused to determine the feasibility and maximum tolerance dose of Ashwagandha with liposomal doxorubicin (DOXIL) in recurrent ovarian cancer patients. The study contains two parts. In part 1 (phase I), 18 patients with recurrent ovarian cancer eligible for DOXIL therapy will be recruited and three doses of Ashwagandha (2.0 g, 4.0 g and 8.0 g) in the form of tablets along with DOXIL will be evaluated for feasibility and tolerance of ASWD. The full summary is on the listing.
Where, as registered
1 US site in 1 state.
RecruitingNCT06793891
Effects of Ashwagandha Extract on Stress Levels
No phase
Nutraceuticals Research Institute
About 60 people
Started Oct 21, 2024
In plain words A study of ashwagandha in female participants 30 to 59, run by Nutraceuticals Research Institute. It plans to enroll about 60 people at 1 US site.
Provision of signed and dated informed consent form
Stated willingness and demonstrated ability to comply with all study procedures, as well as availability for the duration of the study
Self reported high stress
Baseline score of above-average stress levels on the NRI-SS
5 more inclusion criteria and the exclusion criteria are on the listing.
What it tests, as registered
ashwagandha root; ashwagandha root and leaf; placebo
Registered summary
The purpose of this study is to evaluate the efficacy of two proprietary ashwagandha extracts on stress levels, with secondary outcomes of cognition, energy, and sleep, as compared to a placebo.
Where, as registered
1 US site in 1 state.
RecruitingNCT06714942
Efficacy and Safety of a Proprietary Blend of Ashwagandha Root Extract (Aqueous) in Adult Men and Women With High Stress and Anxiety: A Randomized, Double-blind, Three-arm, Parallel, Placebo-controlled Study
No phase
SF Research Institute, Inc.
About 51 people
Started Oct 25, 2024
In plain words A study of ashwagandha in people 18 to 65, run by SF Research Institute, Inc.. It plans to enroll about 51 people at 1 US site.
Who it lists and where
Who the trial lists, as registered
Lists people 18 to 65; healthy volunteers accepted. Conditions: Stress; Anxiety.
Adults (male and female) aged between 18 and 65 years.
Experiencing signs and symptoms suggestive of stress (e.g., difficulty, concentrating, physical exhaustion, anxiety, restlessness, insomnia, headache, fatigue, loss of appetite, worry, sweating, mental confusion, etc.).
Hamilton Anxiety Rating Scale (HAM-A) total score between 14 and 30 at the screening/randomization visit.
Perceived Stress Scale (PSS) score ≥13 at the screening/randomization visit.
4 more inclusion criteria and the exclusion criteria are on the listing.
What it tests, as registered
Proprietary Blend of Ashwagandha; KSM-66 Ashwagandha root extract; Placebo
Registered summary
This is a Multi-center, Multi-national, Prospective, Randomized, Double-Blind, Placebo- Controlled three arm study to evaluate the efficacy and safety of a Proprietary Blend of Ashwagandha Root Extract (Aqueous) in Adult Men and Women with High Stress and Anxiety. All eligible subjects who meet the Inclusion and Exclusion criteria will be part of the study. Subjects will be informed about the purpose of the study and signed informed consent will be taken. Subjects will be randomized to either one of the three treatment arms. The full summary is on the listing.
Where, as registered
1 US site in 1 state.
RecruitingNCT06716554
Efficacy and Safety of Shatavari for Treatment of Menopausal Symptoms in Women: A Randomized, Double-blind, Three-arm, Parallel, Placebo-controlled Study
No phase
SF Research Institute, Inc.
About 51 people
Started Oct 26, 2024
In plain words A study of ashwagandha in female participants 45 to 55, run by SF Research Institute, Inc.. It plans to enroll about 51 people at 1 US site.
Who it lists and where
Who the trial lists, as registered
Lists female participants 45 to 55; healthy volunteers accepted. Conditions: Menopause; Hot Flashes; Mood.
Menopausal women aged 45 to 65 years with intact uterus and ovaries.
Participants who complained of irregular menstrual cycle in the past 12 months, with a forward or postpone of a cycle more 7 days. At least 2 cycles were missing during the past 12 months, or reported menopause for at least 60 days
Females with complaints of menopausal symptoms, e.g., hot flash, insomnia, migraine, easy irritation, etc.
Body mass index 18-35 kg/m2
4 more inclusion criteria and the exclusion criteria are on the listing.
This is a Multi-center, Multi-national, Prospective, Randomized, Double-Blind, Placebo- Controlled three arm study to evaluate the efficacy and safety of Shatavari for the treatment of Menopausal symptoms in Women. Participants will be randomized to either one of the three treatment arms.Participants will then be asked to either take one capsule containing Shatavari or Shatavari + Ashwagandha or Placebo orally once daily in the morning after breakfast with a glass of water for 8 weeks. The full summary is on the listing.
Where, as registered
1 US site in 1 state.
RecruitingNCT07215689
Effects of KSM-66 Ashwagandha® (300 mg) on Skin and Hair Health in Healthy Men and Women"
No phase
SF Research Institute, Inc.
About 50 people
Started Jul 11, 2025
In plain words A study of ashwagandha in people 18 to 60, run by SF Research Institute, Inc.. It plans to enroll about 50 people at 1 US site.
Who it lists and where
Who the trial lists, as registered
Lists people 18 to 60; healthy volunteers accepted. Conditions: Skin Health; Hair Health.
Healthy adult men and women participants ≥ 18 years and ≤60 years of age.
Willingness to follow the protocol requirements as evidenced by written informed consent.
Participants who were on consistent dietary, hair, and skin product 3 months prior to start of the study and are willing to follow the same during the study.
Participants who agree not to use any medication (prescription and over the counter), including vitamins and minerals, during or before the course of this study.
6 more inclusion criteria and the exclusion criteria are on the listing.
What it tests, as registered
KSM-66 Ashwagandha® capsule; Placebo Capsule(s)
Registered summary
Hair and skin play major roles in protecting the body, and maintaining their health is essential. Poor hair and skin health have become increasingly common due to the stress associated with modern lifestyles. Effective and time-efficient treatments for hair and skin health remain limited. Although hair loss, baldness, and skin issues are not life-threatening, managing these conditions is important because of the psychological and social complications-such as anxiety and depression-they can cause. The full summary is on the listing.
Where, as registered
1 US site in 1 state.
RecruitingNCT07803068
The Impact of 12-week Ashwagandha Supplementation Induced by Resistance Training on Strength, Levels of Neurotrophic and Stress Response Proteins, Oxidative and Psychological Stress, and Cognitive Function in Physically Active Male Adults
No phase
Gdansk University of Physical Education and Sport
About 40 people
Started Sep 1, 2025
In plain words A study of ashwagandha in male participants 25 to 40, run by Gdansk University of Physical Education and Sport. It plans to enroll about 40 people at 1 site, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists male participants 25 to 40; healthy volunteers accepted. Conditions: Strength Training Adaptations; Stress; Sleep Quality; Cognitive Functions; Oxidative Stress; Inflammation.
Minimum 6 months of consistent resistance training experience
Participation in at least two resistance training sessions per week
No use of Ashwagandha, adaptogenic supplements, or medications
No medical contraindications and signed informed consent
The exclusion criteria are on the listing.
What it tests, as registered
Ashwagandha; Placebo; Resistance training
Registered summary
This clinical trial will study the effects of Ashwagandha (Withania somnifera), a natural plant extract, on physical and mental health in adult men. Ashwagandha is known for its potential to reduce stress, support hormonal balance and improve sleep and physical performance. The study will explore how taking Ashwagandha for 12 weeks, with resistance training, affects various health markers such as stress hormones, brain function, muscle strength, body composition, sleep quality, and cognitive abilities. The full summary is on the listing.
Where, as registered
No US site; Poland (1).
Not yet recruitingNCT07210229
The Effectiveness of a Proprietary Ashwagandha Extract on Menopausal Symptoms: A Three-Arm Randomized, Double-Blinded, Placebo Controlled Clinical Trial
No phase
Nutraceuticals Research Institute
About 90 people
Starts Oct 1, 2025 (estimated)
In plain words A study of ashwagandha in female participants 40 to 55, run by Nutraceuticals Research Institute. It plans to enroll about 90 people at 1 US site.
Who it lists and where
Who the trial lists, as registered
Lists female participants 40 to 55. Conditions: Menopausal Hot Flashes; Menopausal Women.
Provision of signed and dated informed consent form
Stated willingness and demonstrated ability to comply with all study procedures, as well as availability for the duration of the study
Baseline score of above-average menopause symptom levels on each of the patient reported scales: NRI-MSS (defined as 22+), the MRS scale (defined as 9+), AND 4+ on the MENQoL.
Confirmation of presence of hot flashes
7 more inclusion criteria and the exclusion criteria are on the listing.
What it tests, as registered
ashwagandha root; ashwagandha root and leaf; Placebo
Registered summary
The purpose of this study is to evaluate the efficacy of two proprietary ashwagandha extracts on symptoms of menopause and hormone levels, as compared to a placebo.
Where, as registered
1 US site in 1 state.
Not yet recruitingNCT07768709
Holistic Healing for Knee Osteoarthritis
No phase
All India Institute of Medical Sciences, Jodhpur
About 300 people
Starts Sep 2026 (estimated)
In plain words A study of ashwagandha in people 30 to 65, run by All India Institute of Medical Sciences, Jodhpur. It plans to enroll about 300 people at 1 site, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists people 30 to 65. Conditions: Knee Osteoarthritis (Knee OA).
Age between 30 and 65 years, including males and females both
Diagnosis of primary osteoarthritis (OA) affecting at least one knee joint.
Kellgren-Lawrence (KL) grading of 1 or 2, indicating mild to moderate OA severity.
Baseline Numeric Rating Scale (NRS) score of ≥ 5 out of 10, indicating moderate to severe pain intensity.
This study is a single-center, three-arm, open-label randomized controlled trial designed to compare the effectiveness of integrated care, standard medical care, and Ayurvedic care in adults with early knee osteoarthritis (Kellgren-Lawrence grades I-II). Knee osteoarthritis is a leading cause of pain, functional limitation, and reduced quality of life, and current management often provides incomplete symptom relief. The full summary is on the listing.
Where, as registered
No US site; India (1).
Not yet recruitingNCT07647081
The Impacts of Ashwagandha Supplementation on Diurnal Cortisol and Stress Among Women
No phase
Oklahoma State University Center for Health Sciences
About 30 people
Starts Jun 2026 (estimated)
In plain words A study of ashwagandha in female participants 18 to 45, run by Oklahoma State University Center for Health Sciences. It plans to enroll about 30 people and lists no sites yet.